BioSpace News Archive

Bio-Techne Corporation and 908 Devices announced a joint collaboration to develop an extended workflow solution for protein characterization.

Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, has been granted a United States patent on the use of beta 1,3 glucan for modulating human immune function and treating intestinal inflammation.

Environmental, Social and Governance (ESG) goals focus on key topics including access and affordability, diversity and inclusion, racial justice and the environment

Motixafortide + G-CSF demonstrated a 4.9-fold increase versus G-CSF alone in achieving primary endpoint of target mobilization in up to TWO apheresis sessions

Industry veteran brings more than 25 years of R&D and commercialization experience, with a focus on building a patient-centric precision oncology company

Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, is a national sponsor of the Colorado Melanoma Foundation, a non-profit organization. Castle will collaborate with the Colorado Melanoma Foundation and Epiphany Dermatology to provide free skin cancer screenings and public education through the Sun Bus initiative.

Ablexis grants rights to use the AlivaMab ® Mouse platform for research, development and commercialization of antibodies

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.

CTP-543 Phase 3 Program for Alopecia Areata Advancing as Planned to Support NDA Filing in Early 2023 Conference Call Scheduled Today at 8:30 a.m. ET

908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products